AstraZeneca PLC
HealthcareNYSE:AZN · New York Stock Exchange
-$2.51 today
Vol 1.39M · Avg 1.95M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
21.1%
avg 15.4%
ROIC
13.0%
avg 7.6%
ROA
9.0%
avg 4.6%
Analysis
ROE is currently the strongest return metric at 21.1% versus its period average of 15.4%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Pascal Claude Roland Soriot | Chief Executive Officer & Executive Director | $8.18M | — | 67 | — | — |
Aradhana Sarin | Chief Financial Officer & Executive Director | $3.63M | — | 52 | — | — |
Lutz Jermutus | Head of Projects | — | — | — | — | — |
Jeffrey Pott | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | — | — | — | — | — |
Pam Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | — | — | 56 | — | — |
Ruth March | Senior Vice President of Precision Medicine - R&D Oncology | — | — | — | — | — |
Iskra Reic | Executive Vice President of International | — | — | — | — | — |
Susan Mary Galbraith | Executive Vice President of Oncology R&D | — | — | 60 | — | — |
Joris Silon | Head of Investor Relations | — | — | — | — | — |
David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit | — | — | 51 | — | — |
Ruud Dobber | Executive Vice-President of BioPharmaceuticals Business Unit | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$2.21M
Net Sentiment
$2.21M
Net selling
Most Active
Sharma Mani
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $2.21M over the last 12 months. That adds up to net selling of $2.21M. Sharma Mani was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -23.2% | +14.4% (15yr)6 analysts |
| Revenue | N/A | N/A | -4.1% | +8.4% (15yr)10 analysts |
| Net Income | N/A | N/A | -23.2% | +16.0% (15yr)10 analysts |
| EBIT | N/A | N/A | -20.4% | +15.7% (15yr)10 analysts |
Analysis
Recent growth has been strongest in Revenue at -4.1% over three years. Forward estimates point to Net Income at +16.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Eli Lilly and Company
NYSE:LLY
$1.08T
Johnson & Johnson
NYSE:JNJ
$578.23B
AbbVie Inc.
NYSE:ABBV
$401.62B
Roche Holding AG
RHHBY
$332.93B
Merck & Co., Inc.
NYSE:MRK
$296.47B
Novartis AG
NYSE:NVS
$292.83B
Amgen Inc.
NASDAQ:AMGN
$191.12B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.61B
Pfizer Inc.
NYSE:PFE
$149.30B
Bristol-Myers Squibb Company
NYSE:BMY
$116.72B
GSK plc
NYSE:GSK
$106.61B
Sanofi
NASDAQ:SNY
$106.50B
Who manages AZN?
AstraZeneca PLC (AZN) lists 11 active executives. The top listed executive is Lutz Jermutus, Head of Projects.
Are AZN insiders buying or selling?
Recent insider activity shows net selling of $2.21M.
Explore More
Continue the stock analysis
Jump to another research area for this company.